Nasdaq · Healthcare
Amylyx Pharmaceuticals, Inc. (AMLX)
As-reported financials and recent SEC filings for Amylyx Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$0
Net income
$-144.7M
Net margin
—
Diluted EPS
$-1.53
ROE
-47.4%
P/E (TTM)
—
Market cap
$1.98B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285,000 |
| Gross profit | — | — | — | $19.2M | — |
| Operating income | $-153.3M | $-314.7M | $38.8M | $-201.3M | $-82.7M |
| Net income | $-144.7M | $-301.7M | $49.3M | $-198.4M | $-87.9M |
| Diluted EPS | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-1.48 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-05-26
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →Go deeper on AMLX
Search Amylyx Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.